Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease
© 2020 Federation of American Societies for Experimental Biology..
Urinary plasminogen/plasmin, or plasmin (ogen) uria, has been demonstrated in proteinuric patients and exposure of cultured podocytes to plasminogen results in injury via oxidative stress pathways. A causative role for plasmin (ogen) as a "second hit" in kidney disease progression has yet to have been demonstrated in vivo. Additionally, association between plasmin (ogen) uria and kidney function in glomerular diseases remains unclear. We performed comparative studies in a puromycin aminonucleoside (PAN) nephropathy rat model treated with amiloride, an inhibitor of plasminogen activation, and measured changes in plasmin (ogen) uria. In a glomerular disease biorepository cohort (n = 128), we measured time-of-biopsy albuminuria, proteinuria, and plasmin (ogen) uria for correlations with kidney outcomes. In cultured human podocytes, plasminogen treatment was associated with decreased focal adhesion marker expression with rescue by amiloride. Increased glomerular plasmin (ogen) was found in PAN rats and focal segmental glomerulosclerosis (FSGS) patients. PAN nephropathy was associated with increases in plasmin (ogen) uria and proteinuria. Amiloride was protective against PAN-induced glomerular injury, reducing CD36 scavenger receptor expression and oxidative stress. In patients, we found associations between plasmin (ogen) uria and edema status as well as eGFR. Our study demonstrates a role for plasmin (ogen)-induced podocyte injury in the PAN nephropathy model, with amiloride having podocyte-protective properties. In one of the largest glomerular disease cohorts to study plasminogen, we validated previous findings while suggesting a potentially novel relationship between plasmin (ogen) uria and estimated glomerular filtration rate (eGFR). Together, these findings suggest a role for plasmin (ogen) in mediating glomerular injury and as a viable targetable biomarker for podocyte-sparing treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 34(2020), 12 vom: 15. Dez., Seite 16191-16204 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Egerman, Marc A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.04.2021 Date Revised 05.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1096/fj.202000413R |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316397997 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316397997 | ||
| 003 | DE-627 | ||
| 005 | 20231225161009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1096/fj.202000413R |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316397997 | ||
| 035 | |a (NLM)33070369 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Egerman, Marc A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2021 | ||
| 500 | |a Date Revised 05.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Federation of American Societies for Experimental Biology. | ||
| 520 | |a Urinary plasminogen/plasmin, or plasmin (ogen) uria, has been demonstrated in proteinuric patients and exposure of cultured podocytes to plasminogen results in injury via oxidative stress pathways. A causative role for plasmin (ogen) as a "second hit" in kidney disease progression has yet to have been demonstrated in vivo. Additionally, association between plasmin (ogen) uria and kidney function in glomerular diseases remains unclear. We performed comparative studies in a puromycin aminonucleoside (PAN) nephropathy rat model treated with amiloride, an inhibitor of plasminogen activation, and measured changes in plasmin (ogen) uria. In a glomerular disease biorepository cohort (n = 128), we measured time-of-biopsy albuminuria, proteinuria, and plasmin (ogen) uria for correlations with kidney outcomes. In cultured human podocytes, plasminogen treatment was associated with decreased focal adhesion marker expression with rescue by amiloride. Increased glomerular plasmin (ogen) was found in PAN rats and focal segmental glomerulosclerosis (FSGS) patients. PAN nephropathy was associated with increases in plasmin (ogen) uria and proteinuria. Amiloride was protective against PAN-induced glomerular injury, reducing CD36 scavenger receptor expression and oxidative stress. In patients, we found associations between plasmin (ogen) uria and edema status as well as eGFR. Our study demonstrates a role for plasmin (ogen)-induced podocyte injury in the PAN nephropathy model, with amiloride having podocyte-protective properties. In one of the largest glomerular disease cohorts to study plasminogen, we validated previous findings while suggesting a potentially novel relationship between plasmin (ogen) uria and estimated glomerular filtration rate (eGFR). Together, these findings suggest a role for plasmin (ogen) in mediating glomerular injury and as a viable targetable biomarker for podocyte-sparing treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a amiloride | |
| 650 | 4 | |a eGFR | |
| 650 | 4 | |a edema | |
| 650 | 4 | |a glomerular | |
| 650 | 4 | |a plasminogen | |
| 650 | 4 | |a podocytes | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Puromycin Aminonucleoside |2 NLM | |
| 650 | 7 | |a 58-60-6 |2 NLM | |
| 650 | 7 | |a Amiloride |2 NLM | |
| 650 | 7 | |a 7DZO8EB0Z3 |2 NLM | |
| 650 | 7 | |a Plasminogen |2 NLM | |
| 650 | 7 | |a 9001-91-6 |2 NLM | |
| 700 | 1 | |a Wong, Jenny S |e verfasserin |4 aut | |
| 700 | 1 | |a Runxia, Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Mosoyan, Gohar |e verfasserin |4 aut | |
| 700 | 1 | |a Chauhan, Kinsuk |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes-Bahamonde, Joselyn |e verfasserin |4 aut | |
| 700 | 1 | |a Anandakrishnan, Nanditha |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Bagiella, Emilia |e verfasserin |4 aut | |
| 700 | 1 | |a Salem, Fadi |e verfasserin |4 aut | |
| 700 | 1 | |a Meliambro, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Azeloglu, Evren U |e verfasserin |4 aut | |
| 700 | 1 | |a Coca, Steven G |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Kirk N |e verfasserin |4 aut | |
| 700 | 1 | |a Raij, Leopoldo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t FASEB journal : official publication of the Federation of American Societies for Experimental Biology |d 1989 |g 34(2020), 12 vom: 15. Dez., Seite 16191-16204 |w (DE-627)NLM01261730X |x 1530-6860 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:12 |g day:15 |g month:12 |g pages:16191-16204 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1096/fj.202000413R |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2020 |e 12 |b 15 |c 12 |h 16191-16204 | ||